Rocket Pharma GC sells 631 shares at $3.381
ROCKET PHARMACEUTICALS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ROCKET PHARMACEUTICALS, INC. (RCKT) reported that General Counsel Martin Wilson sold 631 shares of common stock on 2026-08-18 at $3.381 per share. According to the disclosure, the sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units. After this transaction, Wilson directly holds 673,853 shares, including RSUs that convert to common stock on a one-for-one basis.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 631 | $3.381 | $2K |
Footnotes (2)
- F1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
- F2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
Key Figures
Key Terms
Restricted Stock Units financial
RSUs financial
tax withholding obligations financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did RCKT report for Martin Wilson?
What was the sale price for the Rocket Pharmaceuticals (RCKT) insider transaction?
Does the RCKT filing mention a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.